DATA GUIDANCE TABLES The four data guidance tables propose a range of options for jurisdictions to consider for data collection. Many more options are proposed than are likely to be relevant or possible. The data guidance tables list indicators that are high-level and not cancer type specific, so that they can be applied across all 15 Optimal Cancer Care Pathways. Some jurisdictions with the data capabilities may choose to collect and report on cancer type–specific data at much greater depth than suggested in this guidance Table .Monitoring Policy and Strategy Alignment (question 1) Aspect of embedding Optimal Cancer Care Pathways Possible high-level indicators Data source options to consider Awareness of Optimal Cancer Care Pathways across cancer services and among health and other staff Percentage of cancer services that are actively communicating information about Optimal Cancer Care Pathways to their staff Percentage of cancer health professionals who are of Optimal Cancer Care Pathways Jurisdictional-led survey Communications activity data as a proxy for message reach Formal agreements to adopt Optimal Cancer Care Pathways Number of Memoranda of Understanding (MOU) or other formal agreements to adopt Optimal Cancer Care Pathways Jurisdictional records Incorporation of Optimal Cancer Care Pathways in planning for jurisdictional cancer plans and clinical pathways Number of clinical pathways with explicit reference to Optimal Cancer Care Pathways Number of clinical pathways reviewed in line with Optimal Cancer Care Pathways Explicit reference to Optimal Cancer Care Pathways within jurisdictional and local service policies Explicit reference to Optimal Cancer Care Pathways within Analysis of cancer plans and clinical pathways Jurisdictional-led survey (acknowledge that this will be influenced by planning cycles and timeframes for jurisdictions’ Cancer Control Plans) trial
Percentage of cases discussed at a MDT meeting for which treatment plans are developed by the MDT Local/state Oncology Information Systems Psychosocial care Percentage of patients screened for psychosocial distress Local health service/hospital data, e.g. multidisciplinary team meeting records, patient records Clinical Percentage of patients who were enrolled in a clinical Percentage of clinical trials with nil recruitment Percentage of clinical trials closed early due to low recruitment Hospital clinical registers Survivorship Percentage of patients who have a survivorship plan Local health service/hospital data, e.g. multidisciplinary team meeting records, patient records End-of-life and palliative care Percentage of patients who received chemotherapy during last month of life Percentage of patients with an advanced care directive health service/hospital data, e.g. multidisciplinary team meeting records, patient records Table . Across all Priority Questions (qualitative data) Reporting element Possible high-level indicators Data source options to consider Variation across the pathway Extent to which jurisdiction is able to use available data to identify areas of variation in align with Optimal Cancer Care Pathways, e.g. variation by cancer type, point in cancer pathway, geographic region, patient socioeconomic or other factors Description of data available and how it has been used Jurisdictional records Resource of adopting Optimal Cancer Care Pathways Resources associated with adopting Optimal Cancer Care Pathways Any resource savings associated with adopting Optimal Cancer Care Pathways Map and description of resource implications Jurisdictional records Stakeholder consultations
Enablers for adopting Optimal Cancer Care Pathways What has helped most in working towards Optimal Cancer Care Pathway adoption? What have the successes been? What tips would you share with another jurisdiction seeking to adopt the same Optimal Cancer Care Pathway/s? Synthesis of a breadth of perspectives (across locations and roles) that can be collected in formal and informal ways, such as: Stakeholder interviews Workshops and meetings with key stakeholders Stakeholder survey Opportunistic feedback Challenges for adopting Optimal Cancer Care Pathways What have some of the challenges been in working towards Optimal Cancer Care Pathway adoption? How have these been overcome? As above